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Haemostasis is a physiological process, which 
keeps the blood clot-free inside vessels and 
initiates clotting if a vessel is injured. Under 
normal circumstances, a fine balance is 
maintained preventing both thrombosis and 
bleeding. Hence, disorders that interfere with 
the normal functioning of any of the parameters 
involved in clotting like endothelial lining, 
platelets and clotting factors would lead to 
bleeding. AKUH’s Clinical Laboratory offers 
a wide panel of bleeding and thrombophilia 
testing that can be effectively utilized in proper 
evaluation of the patients with haemostatic 
abnormalities. This issue is an attempt to 
provide physicians with information on 
haemostatic abnormalities that should help 
in screening and diagnosing of the diseases.
The first part of the issue focuses on common 
bleeding disorders. An appropriate work-up 
of suspected bleeding disorder is presented. 
Specialised testing is recommended in consultation 
with a haematologist. It is also important that 
patients who are diagnosed with bleeding disorders 
should be managed optimally. In patients requiring 
frequent blood transfusion, there is increased 
likelihood of transfusion-associated-viral infections 
such as HIV, hepatitis B and C. Recently, Clinical 
Laboratory introduced nucleic acid testing that has 
enhanced safety of blood products by eliminating 
window-period donations. 
The latter part of this issue addresses 
thrombophilia which is an inherited or acquired 
predisposition of an individual for arterial or 
venous thrombosis.  AKUH Clinical Laboratory 
offers a variety of tests that can assist in 
diagnosis and management of not only inherited 
but acquired thrombotic disorders. Protein C, 
Protein S, factor V Leiden and antithrombin 
tests are useful in inherited thrombophilia. Other 
tests like anti-phospholipid antibodies (lupus 
anticoagulants, anticardiolipin antibodies), 
homocysteine, PNH and HIT antibodies are 
reserved for acquired cases. In addition, 
international normalised ration and anti-Xa 
assay, which are used in monitoring of oral 
anticoagulation and low molecular weight heparin 
[LMWH] therapy respectively, are discussed. 
Dr Bushra Moiz 
Associate Editor, LABRAD
From the Editor’s Desk
Pro-coagulants Anti-coagulants
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Physical Examination
The underlying cause can be determined by carefully 
examining the patients. Usually low platelets or platelet 
dysfunction produce muco-cutaneous bleedings [Fig. 
1] while clotting factor defi ciency results in a cavity 
bleed for example within joints, abdominal cavity, 
muscle, etc. [Fig. 2].
 
Laboratory Investigations 
Certain pre-requisites should be met before 
collection of blood samples for lab tests. These are 
listed in Table 2. 
Bleeding is a very common symptom for which 
patients approach doctors. At the same time, 
bleeding disorders are a common reason for a 
general practitioner to consult a haematologist.
Determining the cause of bleeding disorders is 
challenging due to the variability of symptoms 
from patient to patient and requires a stepwise 
approach which traces each case from history to 
laboratory investigations. Questions usually focus 
on three main causes of bleeding: impaired vascular 
integrity, thrombocytopenia or platelet dysfunction 
and deficiency of clotting factors. The clinical 
manifestations of any bleeding disorder depend on 
the nature of defect and its severity.
History
How to Investigate a Bleeding Disorder?
Dr Natasha Ali
Haematology
Table 1.  Questions for a Patient Suffering from a Bleeding 
Disorder
Onset of bleeding – to distinguish between 
hereditary and acquired bleeding disorders
Type of bleeding – whether it is muco-cutaneous or 
within a cavity
Severity of bleeding – patient is asked whether 
the symptoms occur spontaneously or during 
haemostatic challenge e.g. surgical procedures, 
road traffi c accidents, etc.
Frequency of bleeding.
Timing of bleeding episode – whether it occurs 
immediately or is it delayed.
Are other members in the family affected?
Drug history which particularly includes use of 
aspirin or NSAIDS
Nutritional history – defi ciency of vitamin C
In case of an infant presenting with bleeding, 
ask the parents regarding prolonged bleeding 
during child’s circumcision or from his/her 
umbilical stalk
Fig. 1. Petechiae (small pinpoint cutaneous bleeding due to platelet defect 
or low platelets)
Fig. 2. Hemarthrosis in a Hemophilia patient – bleeding within the knee
joint secondary to defective coagulation
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Screening tests: Any patient with a bleeding disorder 
should be tested for basic coagulation profi le. The 
results of these will determine whether more specifi c 
tests are required for diagnosis. These tests are listed 
in Table 3.
Specialised tests: Based upon the screening test results, 
second line investigations are ordered for further work 
up. Different approaches are used to diagnose a patient 
depending on clinical details and screening tests. The four 
possible common scenarios are described below:
Case 1
If only PT is prolonged with normal platelet count and 
APTT, then factor VII defi ciency should be suspected 
[Fig. 3]. Factor VII assay will help in establishing 
defi nitive diagnosis.
Case 2
If an isolated APTT elevation is observed and the 
patient has bleeding tendency then the APTT mixing 
test can help to differentiate between factor VIII and 
IX defi ciency. Factor XI is also a remote possibility 
[Fig. 4]. Von Willebrand Disease can lead to raised 
APTT with elevated bleeding time. Presence of lupus 
anticoagulants or factor XII defi ciency can increase 
APTT but patient will have no bleeding symptoms in 
this case.
Case 3
Combined elevation of PT and APTT raises the 
possibility of defi ciencies of factors in common 
pathways such as I, II, V and X. Common causes are 
vitamin K defi ciency in neonates or infants and liver 
disorders in adults. Anticoagulation therapy also leads 
to raised PT and APTT [Fig. 5].
PT-
APTT-N
Platelet-N
No bleeding
Mild factor VII 
defi ciency, Use of oral 
anticoagulants
Bleeding
Severe factor VII 
defi ciency
Table 2. Pre-analytic Considerations for Coagulation Testing
Patient should not have received recent transfusions 
(blood, plasma products and platelets)
Patient  should not be on medications like Aspirin, 
NSAIDS or antibiotics (penicillin)
Patient should not be in stress (as it increases factor 
VIII levels)
Patient should not be pregnant (as it increases Von 
Willebrand factor antigen levels and factor VIII)
CBC including platelet count and peripheral fi lm 
review
Bleeding time
Prothrombin time [PT]
Activated partial thromboplastin time [APTT]
Urea clot lysis test for factor XIII
Table 3 Screening Test for Investigating Bleeding Disorders
Fig. 3. Algorithm for Isolated Prolonged PT
Fig. 4. Algorithm for Isolated Prolonged APTT
Mild bleeding
vWD
PT-N
APTT- 
Platelet-N
Unprovoked
Injury related
Mild to moderate Hae-
mophilia A & B
Severe XI defi ciency
Severe bleeding
Severe Haemophilia
Type III vWD
Fig. 5. Algorithm for Combined Elevation of PT and APTT
PT-
APTT-
Platelets-N
No bleeding
Mild defi ciency of com-
mon pathways factors
Bleeding
Defi ciency of common 
pathway factors. Combined 
factor V&VIII defi ciency
Vitamin K defi ciency
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Fig. 6. Algorithm for Eelevation of all Primary Screening Investigations.
Case 4 
Profound disturbance of primary screening results 
are indicative of global haemostatic abnormalities 
such as advanced hepatic disorder or disseminated 
intravascular coagulation (DIC) (Fig. 6).
In summary, while investigating a patient for suspected 
bleeding disorder, a thorough clinical history and 
physical examination is of paramount importance 
since majority of the disorders can be diagnosed with 
these two tools. Additionally, appropriate laboratory 
testing and timely consultation with a haematologist 
experienced in dealing with bleeding disorders are 
PT-
APTT-
Platelets-r
No bleeding
Same causes
Bleeding
DIC Liver disease
Lupus anticoagulants
the key features of successful management of these 
patients.
Nucleic Acid Testing at AKUH
In recent years, despite improvements in serological 
tests for HCV, HBV and HIV infections, instances 
of viral transmission via transfusion still occur 
because of donations that take place while a donor 
is either in the pre-seroconversion window phase, 
infected with immunovariant viruses, or a non-
seroconverting chronic carrier.
What is Nucleic Acid Testing and how does it help?
Nucleic Acid Testing, (NAT) is a highly sensitive 
molecular method of testing blood donations for 
viral nucleic acid. It is used to detect low level of 
viral genetic material present in the blood specimen 
even before the body begins producing antibodies in 
response to the virus. 
NAT significantly reduces the ‘window period,’ 
which is the time between donor exposure to the 
virus and the appearance of antibodies [Fig 1]. By 
reducing the window period it further diminishes 
occurrence of disease transmission via transfusion. 
The performance of the NAT assay is essentially 
dependent on both its analytical and clinical 
sensitivity and specificity. The analytical sensitivity 
is generally determined by testing dilutions of 
standardised materials such as WHO International 
Standards and subsequent calculations of 95 per 
cent Limit of Detection (LOD).  A NAT can be 
conveniently performed on a mini-pool which is a 
pool of six test samples.
Countries that have introduced NAT have 
encountered a decrease in residual risk of viral 
transmissions. Although other safety measures such 
as more stringent selection of blood donors have 
contributed as well as a marked decrease is evident 
between pre- and post-NAT implementation. The 
residual risk for HCV transmission prior to NAT 
was 0.64 cases per million in France and 3.94 per 
million in Spain which decreased to 0.1 per million 
and 2.33 per million respectively after NAT was 
adopted. HIV NAT yield rates were estimated at 
0.3 per million donations in France and Spain as 
opposed to 0.59 and 2.48 respectively preceding 
NAT incorporation. There is potential that next 
generation NAT testing could completely eradicate 
transfusion risk of HIV, HCV and HBV.
Sana Chundrigar 
Molecular Pathology
Fig. 1. Window period of HIV, HCV and HBV    
11 days 25 days
12 days 75 days
Detection of HIV I and II         
Detection of HCV         
Detection of HBV         
25 days 60 days
NAT testing
Ag & Ab Detection
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1. Lysis, stabilisation     2. Capture  3. Wash   4. Elute
and deproteination
NAT at AKUH
The quality of blood products at the AKUH has further 
improved by the recent addition of NAT testing in the 
blood donor screening programme. There is automated 
pooling of blood donations, sample preparation, 
amplifi cation (real time polymerase chain reaction or 
PCR) and detection. [Fig.2]. 
Before authorising for general use the NAT test 
was validated on more than 1000 blood donations. 
So far up to 18,000 blood donations have been 
screened by NAT assay and unsurprisingly it 
has captured many window period positive 
specimens. 
Fig. 2.  Steps in Nucleic Acid Extraction 
Real time data collection allows monitoring of 
the PCR process in each individual cycle instead 
of end point measurement after completion of all 
cycles [Fig.3].
Fig. 3. Principles of the Real Time PCR
Lab Diagnosis of von Willebrand Disease
Von Willebrand Disease (VWD) is an autosomally 
inherited congenital bleeding disorder resulting 
from deficiency or dysfunction of von Willebrand 
factor (VWF). The predominant clinical problems 
are muco-cutaneous bleeds. Therefore, patients 
usually present with petechiae, oral and gum 
bleeding, nose bleeding or epistaxis. Excessive 
menstrual loss or menorrhagia is a common 
bleeding problem in women of reproductive 
age. Circumcision acts as a good haemostatic 
challenge in case of males and therefore boys may 
be diagnosed earlier than girls. VWD has three 
clinical types based on von Willebrand Antigen 
(VWAg) levels.
Laboratory assessment for Von Willebrand Disease
Following are the laboratory tests which should be 
performed for the laboratory diagnosis of VWD. 
Bushra Afaq and Dr Bushra Moiz
Haematology
Bleeding time: It is performed by IVY method. Its   
reference range is between 1-6 minutes
APTT: A clotting assay having a reference range 
between 25-35 seconds.
VWAg: A quantitative determination of von 
Willebrand activity by turbidimetric method. Its
reference range is between 50-160 per cent.
F-VIII: A clotting assay having a reference range 
between 50-150 per cent.
R-COF: A quantitative determination of F-VIII 
Ristocetin Cofactor activity using aggregometry 
technique. Its reference value is >40 per cent.
RIPA: Ristocetin platelet induced aggregometry. 
Normal platelets show response to standard strength 
of ristocetin but fail to respond to a lower dose.
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AKUH’s Clinical laboatory offers a variety of tests required for diagnosis and characterisation of VWD. 
Results of the above stated laboratory tests are summarized in the Table 1.
r   Decreased activity in comparison to reference range
  More than normal range
N   Normal
L    Subnormal activity
Normal Type 1 Type 
2A
Type 
2B
Type 
2M
Type 
2N
Type 3 PLT-
VWD
VWF:Ag N
N
N
N
N
N
VWF:RCo
FVIII
RIPA
BT
Platelet
Count
L or r
L or r
N or r
often N
N or 
N N N or r N N N r
  N N  
r often N r N often Nabsent
N or r N or r N or r r 1-9 IU/dL N or L
r r r N or L absent r
ror L ror L ror L N or L absent ror L
Table 1. Expected Laboratory Values in Subtypes of VWD
Scoring Systems in Diagnosis of Disseminated 
Intravascular Coagulation 
Dr Natasha Ali 
Haematology
The liver is the most important organ involved 
in the regulation of haemostasis. Most of the 
clotting factors, their inhibitors and a number of 
proteins responsible for fibrinolysis are produced 
in the liver. Therefore, liver disease impacts both 
primary and secondary haemostasis pathways 
through a number of different mechanisms. 
Abnormalities of the clotting cascade are the 
predominant features of acute and chronic liver 
disease. In some patients suffering from hepatic 
disease, physicians are faced with the diagnostic 
challenge of an underlying bleeding or thrombotic 
diathesis due to overlap between various clinical 
syndromes including Disseminated Intravascular 
Coagulation (DIC).
According to the International Society of Thrombosis 
and Haemostasis (ISTH), DIC is a syndrome 
characterised by a systemic intravascular activation 
of coagulation, with loss of localisation, arising from 
different causes. It can originate from and cause 
damage to the microvasculature, which if suffi ciently 
severe can produce organ dysfunction. ISTH also 
proposed that the working defi nition of DIC can be 
divided into two phases:
a)   Non-overt DIC: represents subtle haemostatic 
 dysfunction
b)   Overt DIC: de-compensated phase of non-overt 
 DIC
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of fi ve or more is considered to be 
compatible with DIC, whereas a score of 
less than five may be indicative (but not 
affirmative) for non-overt DIC. Similarly using 
certain clinical and laboratory findings [Table 
2] a score of five or greater is compatible with 
non-overt DIC and could diagnostically define 
patients with a poor prognosis due to haemostatic 
dysfunction, independent of developing overt 
DIC. 
Following steps are suggested for the diagnosis 
of DIC:
Step 1: Determine if the patient has an 
underlying condition associated with DIC. If no 
underlying is present then do not proceed further.
Step 2: Order screening coagulation tests and 
decide whether patient has overt or non-overt 
DIC.
Dr Farrukh Ali Khan 
Haematology
Plasma and Platelet Transfusions in Liver 
Diseases
Liver disease impacts both the primary and 
secondary haemostatic pathways through a 
number of mechanisms. Historically, liver disease 
associated coagulopathy has been considered a 
major contributor to bleeding complications. 
Both acute liver failure (ALF) and chronic liver 
disease (CLD) result in reduced synthesis of 
pro- and anticoagulant factors and are associated 
with thrombocytopenia and platelet dysfunctions. 
Additionally, cholestatic liver disease resulting from 
obstruction in biliary tree is also associated with 
coagulopathy.
Table 1. ISTH Score System for Overt DIC
Screening Tests Findings Points
PLATELET COUNT >100,000/μL  0
 50,000-100,000/ μL  1
 <50,000/ μL  2
PROTHROMBIN (PT upper limit of reference 
TIME range) >3 secs  0
 (PT upper limit of reference range) 
 =3-5.9 secs  1
 (PT upper limit of reference range) 
 ≥6 secs  2
FIBRINOGEN >100mg/dl  0
 <100mg/dl  1
FIBRIN MONOMER No increase  0
 Moderate increase  2
 Severe increase  3
Table 2. ISTH Score for non-Overt DIC
Parameter Findings Points
Diagnosis Not associated with DIC  0
 Associated with DIC  2
Platelet count >100,000/μL  0
 <100,000/μL  1
Prolongation of PT < 3 seconds  0
 > 3 seconds  1
Soluble fi brin or FDP Normal  0
 Increased  1
Antithrombin III Normal    -1
 Low  1
Protein C Normal    -1
 Low  1
Events responsible for DIC in liver disease include 
liver necrosis, impaired endotoxin clearance, 
surgery, shock and ascites recirculation. DIC can 
be recognised as a syndrome suggested by clinical 
signs and laboratory tests. The characteristic 
laboratory findings include: prolonged prothrombin 
time (PT), activated partial thromboplastin time 
(APTT), thrombin time (TT), increased levels 
of fibrin related markers (fibrin degradation 
products, D-Dimer), decreased platelet count, 
fibrinogen level, plasma coagulation factors and 
their inhibitors. More specialised and useful tests 
include: prothrombin activation fragments and 
thrombin-antithrombin complex (TAT).
In 2001, ISTH proposed two separate scoring 
systems for overt and non-overt DIC. The overt 
DIC score consists of a fi ve steps diagnostic 
algorithm, in which a specifi c score, refl ecting the 
severity of the abnormality found, is given to each 
of the laboratory tests [Table 1]. A score 
10
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Routine correction of liver disease associated 
coagulopathy is not required in non-haemorrhagic 
patients.
Vitamin K deficiency is common in ALF and 
cholestatic liver disease and replacement of 
Vitamin K should be considered in these patients. 
Additional therapy may be required during 
episodes of variceal bleeding, surgery and prior to 
invasive procedures. However, the role of plasma 
and platelet infusion prior to invasive procedures 
is not well-established. Paracenteses and central 
venous access can be undertaken safely even in the 
presence of coagulopathy and thrombocytopenia, 
and bleeding post-liver biopsy is not predicted by 
abnormal laboratory markers.
The British Committee for Standards in 
Haematology Blood Transfusion Taskforce (2004) 
suggested that there is insufficient evidence 
to support prophylactic transfusion of fresh 
frozen plasma (FFP) in those with a prolonged 
pro thrombin time (PT) prior to liver biopsy. 
Furthermore, the response to FFP infusion in 
patients with liver disease is highly variable, with 
less than 15 per cent of patients achieving an 
appropriate correction of PT following infusion 
of FFP in one study. The use of FFP can result 
in additional complications;  large  infusion 
volumes  can  lead to volume overload, with 
subsequent exacerbation of  portal  hypertension, 
ascites  and  intracranial hypertension, in addition 
to the risk of infection and transfusion related acute 
lung injury.
In those with disseminated intra vascular 
coagulation (DIC) and bleeding, FFP administration 
may be useful. In this setting, in the presence of 
persistent hypo brinogenaemia and continued 
bleeding following FFP, cryoprecipitate or brinogen 
concentrate may be used.
Platelet  transfusion  should  be  considered  in 
the presence of bleeding and a platelet count 
of <10 x 109/l or prior to invasive procedures 
in those with a platelet count of <50 x 109/l. 
Increments may be poor  following  platelet 
transfusion  in  those  with hypersplenism, active 
bleeding or coexistent infection. Given the lack 
of evidence and efficacy in this area it may be 
more appropriate to adopt an expectant 
management strategy, whereby FFP is reserved 
for those who develop bleeding complications. 
However, this approach is considered too risky 
for some procedures, such as intracranial pressure 
monitor placement in ALF. Further research is 
required to determine an optimal management 
strategy.
Recombinant Factor VIIa (rFVIIa)   has   been 
investigated as an alternative agent for the 
correction of PT in ALF and to reduce blood loss in 
those with bleeding varices, prior to liver biopsy, 
liver resection and during liver transplantation. 
These studies have demonstrated  that  although 
rFVIIa  administration leads  to  normalisation  of 
the  PT,  there  was  no associated reduction in 
bleeding. It is not approved for use in liver disease 
and is associated with a significant increase in 
arterial thromboembolic events when used outside 
its approved indications.
Prothrombin complex concentrates (PCC: 
containing Vitamin K-dependent coagulation 
factors) may have an advantage over FFP with 
smaller volume for delivery of factor replacement 
and rapid correction of haemostatic parameters. 
However, caution is required in patients with liver 
disease due to the risk of DIC and thromboembolic 
complications.  There are no randomised controlled 
trials assessing the efficacy and reduction in 
bleeding risk with PCC in patients with liver 
disease.
Anti-fibrinolytic agents, including tranexamic 
acid, aprotinin and e-aminocaproic acid, have 
been used successfully to control bleeding during 
liver transplantation and reduce transfusion 
requirements in this setting. However, their routine 
use has recently been challenged and their role in 
liver disease outside the transplant setting has not 
been established yet. The use of desmopressin 
(1-deamino-8-d-arginine-vasopressin, DDAVP) 
has been investigated in liver disease but no 
improvement in clinical outcome was seen in 
those with variceal bleeding or those undergoing 
transplantation.
There may be a future role for thrombopoietin 
mimetics in the treatment of thrombocytopenia 
associated with CLD. A phase 2 study of 
Eltrombopag in patients with HCV-associated 
cirrhosis demonstrated its efficacy in raising 
platelet counts sufficiently to allow commencement 
of antiviral therapy.
Further  clinical  trials  are  awaited;  there  may  be 
a further  role  for  these  agents  in  amelioration 
of thrombocytopenia  in  patients  with  CLD  prior 
to procedural interventions.
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Ristocetin Cofactor Activity
Ristocetin Cofactor (RCo) measurement is essential 
for the diagnosis of von Willebrand disease (VWD). 
VWD is an autosomally-inherited congenital bleeding 
disorder that is caused by defi ciency or dysfunction 
of von Willebrand factor (VWF), a plasma protein 
that mediates the initial adhesion of platelets at 
site of vascular injury and also binds and stabilises 
blood clotting factor VIII (FVIII) in the circulation. 
Therefore, defects in VWF can cause bleeding 
by impairing platelet adhesion or by reducing the 
concentration of FVIII. 
VWD is classifi ed into three major categories: 
1. Type 1: a  quantitative defi ciency of VW 
 factor (<30 per cent)
2. Type 2: a qualitative defect of VWF having 
 dysfunctional proteins. Type 2 has further
 subtypes (2A, 2B, 2M, 2N) based on   
 laboratory tests. 
3. Type 3: a severe defi ciency of VWF (<3 per cent)
The RCo Assay is used in the quantitative 
determination of RCo activity in citrated plasma. 
It is particularly useful in detection of type 2A, 2B, 
and 2M VWD, where the VWF: Ag may be normal 
or near normal whereas the VWF: RCo is markedly 
reduced.
RCo Activity in plasma may be determined by 
the agglutination of a standardised suspension of 
platelets in the presence of von  Willebrand factor 
using the antibiotic called Ristocetin. The RCo 
Activity is the in-vitro activity of the von Willebrand 
factor, which is responsible for the agglutination of 
platelets in the presence of Ristocetin. Levels of 
RCo activity are determined by the ability of the 
test plasma and Ristocetin to induce aggregation in 
a standardised platelet suspension.
Principle of the test method is reconstituted lyophilised 
platelets are treated with Ristocetin in the presence 
of varying dilutions of normal standardised human 
plasma having known amounts of RCo Activity. A 
standard curve is thus prepared. Patient plasma is then 
Bushra Afaq
Haematology
Fig. 1. Standard Curve and Interpolation of Ristocetin Cofactor Activity for the Patient  
tested in the presence of Ristocetin and reconstituted 
platelets and an aggregation pattern is determined. 
RCo Activity of test plasma is interpolated from the 
standard curve [Fig. 1].
Results of less than 40 per cent RCo (von 
Willebrand Factor) are generally considered 
abnormal and are indicative of von Willebrand 
disease.
As a quality control of defi cient von Willebrand 
Reference Plasma is included in the test kit to function 
as an abnormal Control. The RCo value of this Control 
is less than 30 per cent.
The RCo assay is considered by many investigators 
to be the single most important assay for VWD. 
However, a complete diagnosis and determination 
of the variant forms of this coagulopathy requires an 
evaluation of family history and lab parameters such 
as Von Willebrand antigen, Factor VIII activity and 
bleeding time.
The test is available at Aga Khan University Hospital’s 
clinical laboratory.
12
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What is thrombophilia?
Heritable thrombophilia is an increased tendency 
towards venous thrombosis. Initially the terminology 
was reserved for inherited disorders only but later 
the term ‘thrombophilia’ was used loosely for both 
inherited and acquired disorders with a predisposition 
for either venous or arterial thrombosis.
Assessment of thrombophilia
1. Clinical: Assessment of thrombophilia starts 
 with detailed clinical history and physical 
 examination. The patient should be assessed 
 for acquired risk factors, medication and co-
 morbids.
2. Laboratory: The tests are listed in Table 1. 
 All the mentioned tests are offered by the 
 clinical laboratory at AKUH.
All You Need to Know About Thrombophilia 
Screening
Dr Bushra Moiz
Haematology
Selection of patient for heritable thrombophilia
The inherited thrombophilia screening in an unselected 
patient population is not advisable. Since it is genetic, 
testing with personal and family considerations 
therefore patients should be carefully chosen. Not 
every patient with thrombosis requires this testing. 
Table 2 and 3 summarise the conditions in which 
screening should not be performed. The information 
provided is according to the guidelines published by 
the British Committee of Standards in Haematology.  
What are the appropriate timings of testing?
There is seldom any point in striving to obtain 
samples for thrombophilia testing when the patient 
presents with deep venous thrombosis (DVT) 
or pulmonary embolism (PE).  During an acute 
thrombotic episode, patients usually have low 
levels of protein C, protein S and antithrombin III
Table 1. Comprehensive Panel of Thrombophilia Testing
Routine
CBC, PT, APTT, Liver function tests 
and Serum creatinine
Protein C, protein S, anti-thrombin III,
activated protein C resistance(APCR)
Anticardiolipin antibodies (IgM and 
IgGO), lupus anticoagulants, 
serum homocysteine levels   
PNH screening (CD55and 59)
HIT
ADMATS-13 assay
JAK-2 V617F mutation
Specialised
Ancillary 
To determine safety profi le before initiation of 
heparin and warfarin
Required in investigation of heritable 
thrombophilia
Required in acquired thrombophilia
Required for suspected PNH (intravascular 
haemolysis and pancytopenia)
For suspected HIT (heparin induced   
thrombocytopenia)
Needed for suspected TTP (micro-angiopathic 
haemolytic anaemia, thrombocytopenia, renal 
insuffi ciency and neurological defi cit)
For suspected myeloproliferative disorder (MPD) 
with erythrocytosis/leucocytosis/thrombocytosis
PurposeTest
13
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Table 2. Conditions Recommended  for Thrombophilia Screening
Venous thrombosis at an early age ( <40 years) 
Venous thrombosis in  a patient with thrombosis prone family ( >2 symptomatic family members)
Neonates and children with  fulminating purpura (purpura fulminans) for protein C and S
Adults with skin necrosis following warfarin therapy for protein C and S
Case fi nding of asymptomatic relatives for high risk such as protein C and S defi ciencies  in thrombosis 
prone families
Women requiring contraceptives or hormone replacement therapy with high risk thrombophilia in symptom-
atic relative
Pregnancy with previous travel related thrombosis
Asymptomatic pregnant woman with family history of thrombosis which was either unprovoked or provoked 
by pregnancy, combined oral contraceptives (COC) exposure or  traveling
Unselected patients with fi rst episode of thrombosis
First episode of cerebral venous thrombosis
Arterial thrombosis
Paediatric stroke
Hospital acquired venous thrombosis
Asymptomatic relatives of low risk thrombophilia (factor V Leiden, prothrombin gene mutation).
Retinal vein occlusion
First event of an intra-abdominal vein thrombosis
Pregnant women with previous unprovoked thrombosis
Pregnancy with previous  trauma/surgery related thrombotic event
Pregnancy or COC related thrombosis
Unselected patients with upper limb thrombosis
Central Venous Catheters  related thrombosis
Table 3. Conditions Which Should not be Tested for Heritable Thrombophilia
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as the two are consumed in an attempt to natural 
thrombolysis. This results in false low levels of these 
proteins. Testing should be delayed for at least one 
month after discontinuation of oral anticoagulation. 
Pregnancy and oestrogen reduce protein S levels 
significantly and increase resistance to APC. If 
possible, thrombophilia testing should be avoided 
in inter-current illnesses, pregnancy and with oral 
contraceptive usage.
How should I collect blood samples?
The blood sample should be collected in standard 
sodium citrate bottle/blue top vacutainer in a ratio 
of 9:1 for lupus anticoagulant, protein C, S, APC, 
and AT-III. EDTA blood sample is required for HIT, 
PNH and JAK-2. Clotted blood sample is needed for 
anticardiolipin antibodies and homocysteine.
Methodology assays used at AKUH clinical 
laboratory
At AKUH, functional assays are used for heritable 
thrombophilia which have acceptable accuracy and 
precision. Table 4 shows the various tests and their 
methodologies used at AKUH.
How should I interpret the tests?
The thrombophilia screening should be supervised 
by experienced laboratory staff and the clinical 
signifi cance should be made in consultation with an 
experience haematologist who is aware of relevant 
factors that may affect test results in each case. The 
factors affecting thrombophilia testing resulting in 
spurious assessment is listed in Table 5.
Do I need repeating the tests?
Repeat testing for protein C, S and anti-thrombin III is 
indicated and a low level should be confi rmed on one 
or more separate samples. Diagnosis of defi ciency 
should not be made on a single abnormal test.
Would the testing affect patient management?
Initiation and intensity of anticoagulation following 
diagnosis of acute venous thrombosis in a patient 
should be the same with or without thrombophilia. 
Testing of thrombophilia in selected patients with 
strong family history of unprovoked thrombosis 
may influence decision regarding duration of 
anticoagulation.
Table 4. Tests and their Methodologies Used at AKUH Clinical Laboratories
Clinical utility Method
Heritable thrombophilia
Protein C
Protein S
Antithrombin III
APCR
Lupus anticoagulant
Anticardiolipin antibodies
Serum homocysteine
Acquired thrombophilia
Chromogenic assay
Clotting based assay
Chromogenic assay
Clotting based assay
Clotting based assay
ELISA
Immunogenic microparticulate 
assay
Tests
PNH
HIT
TTP
MPD
PNH screening
HIT screening
ADAMTS-13
JAK-2  V 617 F
Gel immunoassay
Gel immunoassay
ELISA
PCR
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 Table 5. Conditions Giving Rise to Misleading Results in Thrombophilia Screening
Acute thrombosis
Anticoagulants- heparin and warfarin
Direct thrombin inhibitors e.g. argatroban, lepirudin, bivalirudin
Liver disease
Pregnancy and COC
Membrane phospholipids participate in important 
cellular functions including exchange of 
metabolites across membrane, transferring 
molecular signals and serving as a platform 
for the assembly of protein-lipid complexes. 
Natural autoantibodies to complexes of 
negatively charged phospholipids and plasma 
proteins are present in low concentrations (1-5 
per cent) in healthy individuals. However, their 
concentration is markedly increased in certain 
diseases and therefore is used for diagnosis and 
monitoring of the disease entity.
Antibodies to phospholipids are mainly of 
three types which are closely related: lupus 
anticoagulant antibodies (LAC), anti-cardiolipin 
antibodies (ACA) and anti-β2 – glycoprotein 
I antibodies (anti-B2GPI). Minor phospolipid 
antibodies include prothrombin, annexin V, 
phosphatidylserine and phosphatidylinositol. 
The antiphospholipid antibody assays vary 
in different patients with similar clinical 
manifestation. Some patients are positive 
in all antiphospholipid antibody assays while 
others are only positive for one or two of these 
assays.
 
ACA are autoantibodies against mitochondrial 
phospholipid and were the first phospholipid 
antibodies to be identified. It is less antigenic 
compared to other APA. It may elevate in 
conditions such as acute infection (32 per cent), 
Dr Maria Riaz 
Chemical Pathology
Signifi cance of Antiphospholipid Antibodies
rheumatoid arthritis (4-25 per cent), drug induced 
lupus (47 per cent) and elderly patients (52 per 
cent). It either binds directly to phospholipids or 
may require the presence of β 2-GP1.
LAC has higher thrombotic potential than ACA. 
It is also thought to be more specific compared 
to ACA. LAC has recently been thought to react 
against prothrombin and results in prolonged 
APTT; 85 per cent of APS patients have both 
LAC and ACA.
β 2-GPI antibody is an apolipoprotein with 
anticoagulant activity through the inhibition 
of the conversion of prothrombin to thrombin, 
regulation of protein S, and/or activation of 
platelets. β 2-GPI is often included in ACA 
assays to ensure the detection of both β 2-GPI 
dependent as well as independent ACAs. β 
2-GPI dependent ACA seems to be related 
to autoimmune conditions whereas β 2-GPI 
independent ACA tend to be associated more 
with infections. β 2-GPI alone is found in 11per 
cent of the APS patients.
The antiphospholipid antibody syndrome is also 
known as the Hughes syndrome or the “sticky 
blood syndrome.” It is a hypercoagulable 
condition associated with both venous and 
arterial thrombosis and pregnancy related 
morbidities. APS may also show other 
manifestations like thrombocytopenia and/or 
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hemolytic anaemia, livido reticularis, cardiac 
valve disease and nephropathy. Non-thrombotic 
neurologic manifestations of APS include multiple 
sclerosis like syndromes, chorea or migraine 
headaches.
Antiphospholipid antibody syndrome is classified 
as primary or secondary depending on the absence 
or presence of other autoimmune disorders such as 
SLE respectively. 
The Sapporo criteria (2006) classifies the 
antiphospholipid antibody syndrome on the basis 
of one clinical and one laboratory manifestation as 
shown in Table 1 while the indications for testing 
are mentioned in Table 2.
Table 1. Sapporo Criteria for the Diagnosis of Antiphospholipid 
Antibody Syndrome
ACA are detected by enzyme immunoassays. LAC 
have been detected using phospholipid responsive 
clotting tests such as APTT, Kaolin clotting time (KCT) 
and dilute Russell’s viper venom test (DRVVT). LAC 
produces prolongation of phospholipid-dependent 
clotting in vitro. Despite the “anticoagulant effect” in 
vitro, these antibodies actually cause coagulation in 
vivo, in the form of arterial and venous thrombosis. 
At the AKUH Clinical Laboratory, Karachi, the 
quantitative anticardiolipin IgG and IgM are measured 
using the DIASTAT anti-cardiolipin kit by indirect 
enzyme immunoassay method. The ACA panel 
includes only IgG and IgM antibodies. The incidence 
of IgA ACA is extremely low and their determination 
is not helpful in the investigation of thrombosis or 
other manifestations of the APLA syndrome.
For the detection of lupus anticoagulant, the AKUH 
Clinical Laboratory uses the simplifi ed DRVVT 
method. In this method the LA1 (screening reagent) and 
LA2 (confi rmation reagent) are utilised and prolonged 
clotting time is observed in positive samples.
Positive and strongly positive results for phospholipid 
antibodies (≥or 60 GPL and/or MPL) are a diagnostic 
criterion for antiphospholipid syndrome (APS). 
Lesser levels of phospholipid antibodies and 
antibodies of    the IgA isotype may occur in patients 
with clinical signs of APS but the results are not 
considered diagnostic.
 
Surveys indicate that results of phospholipid antibody 
tests can be highly variable and results obtained 
with different commercial immunoassays may yield 
substantially different results. ACA should be retested 
after six to eight weeks to rule out transient antibodies 
that are usually of no clinical signifi cance.
Clinical   
   
1. Arterial or vessel thrombosis  – other than   
 superfi cial venous thrombosis in any tissue or 
 organ 
2. One or more unexplained deaths of a 
 morphologically normal fetus (at/beyond the 
 10th week of gestation)  
3. Three or more unexplained consecutive 
 spontaneous abortions (before the 10th week 
 of gestation) with no maternal anatomic/
 hormonal abnormalities and no paternal/  
 maternal chromosomal causes 
4. At least one premature birth of a
 morphologically normal neonate (before the   
 34th week of gestation) due to eclampsia/
 severe pre-eclampsia/placental insuffi ciency
Laboratory
1. Anti-cardiolipin IgG and/or IgM by ELISA on 
 two or more occasions, not less than 12 weeks 
 apart 
2. Anti-β2 glycoprotein I IgG and/or IgM by 
 ELISA on two or more occasions, not less than 
 12 weeks apart
3. Lupus anticoagulant detected on two occasions 
 not less than 12 weeks apart according to the 
 guidelines of the International Society of 
 Thrombosis and Haemostasis
Table 2. Indications for Testing Antiphospholipid Antibodies
Clinical criteria as mentioned in Table 1
Presence of a systemic rheumatic disease 
especially SLE
Presence of an unexplained cutaneous circulatory 
disturbance like, livido reticularis or pyoderma 
gangrenosum
Unexplained thrombocytopenia or haemolytic 
anaemia
Possible nonbacterial, thrombotic endocarditis
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Elevated plasma homocysteine is associated with 
increased incidences of cardiovascular mortality, 
stroke, dementia and Alzheimer’s disease, bone 
fracture and higher prevalence of chronic heart failure. 
It was also shown that elevated plasma homocysteine 
is a risk factor for preclampsia and neural tube 
defects (NTD). Homocysteine has been implicated 
in atherosclerotic and thrombotic vascular disease in 
the general and in end-stage renal disease (ESRD) 
population as well.
Homocysteine is a sulphur containing amino acid, 
formed normally during metabolism of another 
sulphur containing amino acid methionine. It is 
metabolised by pathways, remethylation and trans-
sulfuration of methionine (Fig 1). Approximately 50 
per cent of methionine is metabolised to cystathioinine 
by cystathionine beta synthesase (CBS). This is 
a one way reaction that permanently removes 
homocysteine from the methionine cycle and initiates 
the transsulfuration pathway for methyl group either 
from N5 mehyltetrahydrofolate (in all tissues) or from 
betaine (in liver and kidneys) to form methionine. The 
former methylation step requires folate and vitamin 
B12 as cofactors in trans-sulfuration pathways and 
is effective when there is excess of methionine or 
cysteine synthesis is required.
Homocysteine as a Risk Factor of Thrombosis
Rakhshanda Maher  
Chemical Pathology
An elevated plasma homocysteine level has been 
found in patients with thrombotic disorders. In 
actual thrombosis is a formation of blood clot inside 
the blood vessel, obstructing the blood fl ow through 
the circulating system. It is mainly classifi ed into 
venous and arterial thrombosis. The mechanism by 
which homocysteine contributes to atherothrombosis 
is complex and in vivo relevance is uncertain. 
However in the Journal of Clinical Investigation-
2009, Jacoviner and his colleagues have reported a 
unique mechanism in vivo by which homocysteine 
may contribute to vascular disease. Accordingly, 
there is impairment in the synthesis of endothelial 
surface plasminogen which is the major fi brinolytic 
agent. This leads to micro vascular dysfunction and 
subsequent macro vascular occlusion in individuals 
with hyperhomocystenemia.
Most studies so far have indicated normal 
plasma homocystiene level to be in the range of 
5 to 15 ul/L. However this does not imply that 
there is no risk associated with homocystiene 
levels between 10 to 15μl/L.
In 1990, the cut-off for homocysteine was 
greater than 20μmole/L. This number 
continued to go lower, and today, a level 
somewhere around 12μmole/L is considered 
as the recent cut-off. Homocysteine analyses 
in The National Health and Nutrition 
Examination Survey III (NHANES)  results 
shed some light into what constitutes ‘normal’ 
homocysteine levels in the US population. 
A study conducted in 1999 by NHANES 
investigators (published in Ann Intern Med 
1999; 131:331) showed that homocysteine 
levels continue to increase as a person ages, and men 
have a higher mean concentration than women.
The AKUH Clinical Laboratory in Karachi, measures 
the quantitative anticardiolipin IgG & IgM are 
measured using the DIASTAT anti-cardiolipin kit by 
indirect enzyme immunoassay method. The ACA panel 
includes only IgG and IgM antibodies.The incidence 
of IgA ACA is extremely low and their determination 
is not helpful in the investigation of thrombosis or 
other manifestations of the APLA syndrome.
Fig. 1. Metabolism of Homocysteine
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CD55 and CD59 for the Diagnosis of PNH
Paroxysmal nocturnal hemoglobinuria (PNH) 
is an acquired clonal hematopoietic stem cell 
disorder induced by exposure to chemicals or 
certain antibiotics and characterised by chronic 
intravascular haemolysis, venous thrombosis, 
defective haematopoiesis, frequent episodes of 
infection and rarely, leukemic transformation.
Pathophysiology of PNH
Patients with PNH have a defective gene 
called PIG-A, involved in the biosynthesis of 
glycosylphosphatidylinositol (GPI).Without 
GPI, important regulatory proteins (e.g. CD55 
or “DAF” and CD59 “MIRL”) cannot bind to 
the surface and protect blood cells from attacks 
of various proteins called complements. This 
may result in a breakdown of erythrocytes and 
release of haemoglobin which causes the urine 
to turn dark during an episode (or “paroxysm”) 
of haemolysis, though this is not found in all 
cases.
There are certain diagnostic tests which are 
used in the diagnosis of PNH including Ham’s 
test, sucrose lysis test, and CD55 and CD59 
analysis by flow cytometry and by using gel 
card technique.
CD55 and CD59 determination by gel card 
technique
 
Gel agglutination assay for PNH is a simple 
method for screening red cells for deficiency 
of GPI linked protein. For optimal results, 
the determination should be performed using 
a freshly drawn blood sample preferably into 
EDTA, citrate or heparin, CPD-A anticoagulant.
Fatima Azra Ausat
Haematology
Gel card tubes contain monoclonal antibodies 
against CD55 and CD59; if cells express both 
antigens the cells agglutinate by forming 
antigen antibody complexes and bind the 
mouse antibodies. After centrifugation through 
the gel, cells carrying antibodies, confirming 
the presence or MIRL or DAF, will show 
a positive reaction, grade three-four in the 
micro-tubes indicates the presence of a normal 
cell population. Cells deficient in MIRL or 
DAF show a negative reaction as a compact 
button at the bottom of the micro tube [Fig.1]. 
Double population of cells indicates a weak 
positive PNH test. Whenever it is necessary to 
know the amount of cells affected, a quantitative 
test procedure such as flow cytometry should be 
performed following a positive ID-PNH test.
PNH is only diagnosed where both MIRL and 
DAF are shown to be deficient.
Fig. 1. Gel card showing results for a normal person (three gel tubes on the 
left) and from a patient suffering from PNH (three gel tubes on the right)
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A Disintegrin and Metalloprotease with 
Thrombospondin Type 1 Motif, 13 (ADAMTS-
13) is an enzyme which is released primarily from 
the stellate cells of the liver but is also found in 
platelets and endothelial cells. It is involved in 
the regulation of the size of von Willebrand factor 
(VWF) in plasma. 
ADAMTS-13 maintains primary haemostasis by 
proteolysing ultra-large von Willebrand Factor 
(ULvWF). The latter is the hyperactive form  of 
vWF which is released  from  storage  granules 
(Weibel-Palade bodies)  of  endothelial  cells 
in response to inflammatory stimulation. The 
ULvWF has more affinity for platelets favouring 
platelet aggregation at sites of high shear stress 
with subsequent formation of micro vascular 
thrombi. The ULvWF relies upon ADAMTS-13 for 
its cleavage and its conversion into a less active 
form.
Deficiency of ADAMTS-13 may be congenital 
(Upshaw-Schulman syndrome) or more often than 
not acquired. An acquired deficiency is attributed to 
the presence of auto-antibodies against ADAMTS-
13 which may either inhibit ADAMTS-13 function 
or  may  cause  rapid  clearance  of circulating 
ADAMTS-13.  Inherited or acquired deficiency of 
ADAMTS-13 impairs ULvWF cleavage. Deficient 
proteolysis of ULvWF results in disseminated 
platelet-rich  thrombi  in  the microcirculation 
which  in  turn  cause  typical thrombotic  micro-
angiopathies  resulting  in  end organ ischemia.
The laboratory assessment of ADAMTS-13 levels 
is useful since severe deficiency of ADAMTS-
13 has been proposed as a specific laboratory 
marker of thrombotic thrombocytopenic purpura 
(TTP) or Upshaw-Schulman syndrome. It is 
also seen in conditions like sepsis, disseminated 
intravascular coagulation (DIC) and metastatic 
malignancy.  Mild to moderate deficiency is seen 
in chronic inflammation, hepatic dysfunction and 
pregnancy.
Given  that  severe  secondary  deficiency  of 
ADAMTS-13 might correlate with development of 
widespread microvascular  thrombi and end organ 
injury, determination of ADAMTS-13 activity 
at the time of hospital admission in patients with 
severe conditions  like  sepsis  and  DIC  will 
help  in understanding the extent of the disease. 
It also raises the possibility of novel supportive 
therapies for patients with sepsis and DIC such as 
ADAMTS-13 supplementation and plasma therapy 
because sepsis may have the same pathophysiology 
of severe ADAMTS-13 deficiency for thrombotic 
microangiopathies as idiopathic TTP.
The test is currently offered by clinical laboratories 
of AKUH. It is based on the principle of enzyne 
linked immuno sorvent assay (ELISA) technique. 
Two to three millilitres of blood collected in citrate 
anticoagulant is required for the test. The reference 
range developed at AKUH for ADAMTS-13 is 175-
365 ng/dl.  There is no difference in reference range 
between males and females or adults and children.
Utility of ADAMTS-13 Assay
Dr Farheen Karim Mahar 
Haematology 
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Heparin  is  used  widely  for  the  prevention 
and treatment of thromboembolic diseases, 
during  procedures  of  haemodialysis  and 
cardiopulmonary bypass  surgeries.  Two types 
of heparin preparations widely in use today 
are unfractionated heparin (UFH) and low 
molecular weight heparin (LMWH). The 
inconvenience and limited precision of monitoring of 
(UFH) therapy has contributed to the increasing use 
Anti-factor Xa Assay
Dr Natasha Ali
Haematology
of LMWH preparations. The pharmacokinetic 
properties of LMWH are different from (UFH) 
and allows for easily monitored anticoagulant 
effects of a given dose. Monitoring is, 
however, recommended in clinical settings 
like renal insufficiency, obesity, paediatric 
patients and those on prophylactic anticoagulant 
therapy in conditions like malignancy 
or anti-phospholipid syndrome. Anti-
Critical International Normalised Ratio
Dr Shabneez Malik
Haematology 
Oral anticoagulant therapy is commonly used in 
the management of venous thrombosis such as 
deep venous thrombosis of  veins and pulmonary 
embolism. 
Previously, laboratories used to report prothrombin 
time as a part of anticoagulation monitoring. 
It was then found out that the prothrombin time 
varied due to the difference in sensitivity of 
various thromboplastins used in different clinical 
laboratories. World Health Organization (WHO) 
devised the term “International Normalised 
Ratio” (INR) to reduce this inter-laboratory 
variability.This term is self-explanatory. This is 
a ratio of patient’s prothrombin time divided by 
reference normal prothrombin time to the power 
of a coefficient which is known as “international 
sensitivity index.” This relates the sensitivity 
of a given thromboplastin to the sensitivity of 
WHO’s first international reference preparation of 
thromboplastin (given an ISI of 1.0). 
Monitoring of INR is critical in warfarinised 
patients. Because of the narrow therapeutic 
INR, patients on warfarin are stabilised within 
a range of 2-3.  Elevated INR can lead to 
haemorrhagic complications on one hand while 
sub-therapeutic INR can result in thrombosis. 
Therefore accurate monitoring of INR is crucial 
in preventing bleeding and thrombosis. The 
goal of establishing critical INR is to alert 
the physician to a potentially life threatening 
bleeding or thrombosis requiring urgent 
intervention. Critical INR value needs to be 
established at local level as the line between 
therapeutic and critical INR is thin.  
The Seventh American College of Chest Physicians 
Conference on Antithrombotic and Thrombolytic 
Therapy recommended therapeutic intervention 
in oral anticoagulant patients who have an INR 
of 5.0 or greater. Therefore, critical INR in many 
laboratories is 5.0.  In 2000 College of American 
Pathologist survey, 166 laboratories (27 per cent) 
had chosen a critical INR of 5.0. Similarly an INR 
below 1.5 should be considered critical for a patient 
on oral anticoagulation as the patient is at risk for 
thrombosis.
At AKUH, an INR of 5.0 or above is considered 
critical. At this INR, the patient is contacted for 
clinical details including medications. Patients are 
advised to repeat INR and to consult their primary 
physicians on emergency basis.  
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factor Xa assay is used to monitor LMWH 
therapy.
Principle of anti-factor Xa is based on the fact 
that both factor Xa and antithrombin III are 
added in excess amounts to the test plasma 
and the residual factor Xa activity is inversely 
proportional to the heparin concentration. The 
test is based on the assumption that the patient 
has a normal concentration of antithrombin III.
The test is performed by adding a known 
amount of factor Xa and antithrombin to the 
plasma of the patient. If heparin or LMWH 
is present in the patient plasma, it will bind 
to antithrombin and inhibit factor Xa. The 
amount of residual factor Xa is inversely 
proportional to the amount of heparin in the 
plasma. The amount of residual factor Xa is 
detected by adding a chromogenic substrate 
that resembles the natural substrate of factor 
Xa. Factor Xa cleaves the chromogenic 
substrate, releasing a coloured compound 
that can be detected by a spectrophotometer. 
Results  are  reported  as anticoagulant 
concentration  in  anti-factor  Xa units/ml, 
such that high anti-factor Xa values indicate 
high  levels  of  anticoagulation. Deficiencies 
of antithrombin in the patient do not affect 
the assay, because excess antithrombin is 
provided in the reaction.
Specimen is  col lected in  sodium ci t ra te 
bot t le  (blue top)  about  four  hours  af ter 
subcutaneous inject ion of  LMWH. Blood 
sample should be del ivered to  the laboratory 
immediately or  e lse  fa lsely low values  may 
occur  (because platelets  re lease platelet 
factor  4  (PF4)  which can neutral ise  heparin 
or  LMWH).  For  the same reason,  plasma 
must  be separated from cel ls  as  soon 
as  possible ,  ideal ly  within one hour  of 
specimen col lect ion.  Plasma can be s tored 
for  two hours  a t  room temperature  or  can be 
frozen for  la ter  tes t ing.
Laboratory is specifically notified as to which 
drug should be measured (heparin, LMWH). 
Limitations of this test include cost issues 
and less ready availability than the activated 
partial thromboplastin time (APTT) for 
heparin monitoring.
Patients not on anticoagulants: 0 unit/ml. 
Therapeutic range for anti-factor Xa for a 
deep venous thrombosis (DVT) patient differs 
according to the type of preparation used.:
Causes of Sub-Therapeutic Anti-factor Xa 
Level
1. Specimen drawn at incorrect time (collection  
 times are four hours after injection of LMWH, 
 six hours after injection of danaparoid).
2. Specimen transportation time longer than two 
 hours.
3. Patient receiving prophylactic dose, therefore,  
 therapeutic range is not applicable and anti- 
 Xa level is actually appropriate for dose.
Causes of Supra Therapeutic Anti-factor Xa 
Level
1. Renal failure (with LMWH or danaparoid) 
 because of decreased renal clearance.
2. Heparin contamination, if specimen was 
 drawn from an IV heparinised line. 
Table 1. Reference Ranges for Anti-Factor Xa
Heparin: 0.3-0.7 units/ml
LMWH: 0.4-1.1 units/ml for twice daily 
subcutaneous dosing. For once daily 
subcutaneous LMWH dosing, the therapeutic 
range is less certain but is approximately 1-2 
units/ml.
Target range for DVT prophylaxis (prevention): 
There is no defined target range for prophylaxis 
of deep vein thrombosis DVT because such 
anticoagulation is not usually monitored. 
When anti-Xa levels have been measured, 
mean values are usually <0.45 units/ml.
Therapeutic range UFH: 0.3-0.7 U/L
Therapeutic range LMWH: 0.5-1.0 U/L
Prophylactic range UFH : 0.1-0.29 U/L
Prophylactic range LMWH: 0.20-0.49 U/L
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Detection of Heparin/Platelet Factor 4 Antibodies
Heparin-induced thrombocytopenia (HIT) is the 
development of thrombocytopenia due to the 
administration of Heparin. HIT predisposes to 
thrombosis and when thrombosis is identifi ed 
the condition is called “Heparin-induced 
thrombocytopenia and thrombosis (HITT).” Clinical 
features associated with HIT syndrome primarily 
include a decreased platelet count, risk of venous 
or arterial thromboembolic complication and the 
development of antibodies against a complex of 
heparin and PF4. HIT is a life and limb threatening 
condition. The diagnosis is made on clinical suspicion 
requiring laboratory confi rmation. The testing is 
recommended in all patients whose platelet count 
drop by 50 per cent of baseline within three to fi ve 
days of heparin administration. HIT is observed both 
with unfractionated heparin and with low molecular 
weight heparin though the risk is less with latter.
Several tests are available for detection of Heparin/
PF4 antibodies in the laboratory [Table 1].  Aga Khan 
University Hospital, Clinical Laboratory uses ID-
PaGIA Heparin/PF4 Antibody Gel Test for detection 
of these antibodies against this complex. The ID-
Safi a Naz
Haematology
PaGIA Heparin/PF4 antibody test is a particle gel 
immuno assay (PaGIA). High density synthetic 
polymer particles are coated with heparin/platelet 
factor 4 complex (HPF4). When these particles are 
mixed with patient serum-specifi c antibodies of any 
immunoglobulin class, they react with the HPF4A on 
the bead surface, causing agglutination. When  the 
reaction mixture is centrifuged through a gel fi ltration 
matrix, agglutinated particles are trapped on top of 
the gel or distributed within the gel (positive reaction) 
while free or  non- agglutinated particles form a pellet 
at the bottom of the micro tube (negative reaction). 
Due to the strong red colour of these particles, the 
result can be read visually with ease [Fig.1]. 
Fig. 1. Heparin/HP4 Gel Card showing Negative results for Patient One 
and Two and Positive results for Patient Three and Four.
Table 1. Recommendation for laboratory Testing for Heparin Induced Thrombocytopenia Antibodies
Test
Particle gel immunoassay 
ID-Heparin/PF4 antibody 
test (ID-H/PF4)
Enzyme linked 
immunosorbent assay 
test (ELISA)
Platelet aggregation test
Serotonin release 
assay/washed platelets 
activation assays
Methodology
Patient serum and PF4 heparin-coated micro-beads are added to the incubation 
chamber of the micro-column card and after fi ve minutes, the card is 
centrifuged. A strong positive result indicated by the agglutinated micro-beads 
remaining top of the column.
It detects all circulating antibodies that bind Heparin PF4 complexes and may 
also falsely identify antibodies that do not cause HIT. Therefore, ELISA is more 
sensitive but less specifi c requiring further testing.
Citrated platelet rich-plasma is used as an initial test for HIT, a positive result 
generally supports the diagnosis of HIT and further testing is not required. 
However negative test does not exclude HIT in a patient with a moderate or 
high pre-test probability for HIT. In this situation washed platelets activation 
assay should be performed.
SRA is considered to be gold standard and is specifi c for the HIT antibodies. 
The platelets are washed and mixed with serum and heparin. The sample is then 
tested for the release of serotonin, a marker of platelet activation. If serotonin 
release assay shows high serotonin release, the diagnosis of HIT is confi rmed.
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The 4th Biennial Course in Chemical 
Pathology
The 4th Biennial Course in Chemical Pathology 
and Endocrinology was organised by Pakistan 
Society of Chemical Pathologist (PSCP) at Armed 
Forces Institute of Pathology (AFIP), Rawalpindi 
on March 16 and 17, 2012.
The inaugural session was attended by pathologists 
and their trainees from all over Pakistan. Dr 
Farooq Ghani, Section Head Chemical Pathology 
and Director Outreach of Clinical Laboratory, Dr 
Imran Siddiqui, President PSCP, Drs Aysha Habib 
Khan and Shireen Mansoor, members Executive 
Council PSCP from Aga Khan University attended 
the meeting.
In his welcome address at the inaugural session, 
Commandant AFIP, Major General Farooq Ahmed 
Khan, patron PSCP, updated the audience with the 
recent advances and trends in the field of Chemical 
Pathology. Chief Guest Lt General Azhar Rasheed 
(Director General Medical Services, Pakistan 
Army) appreciated the efforts of PSCP in educating 
and treating patients.
The course comprised four teaching sessions 
followed by a workshop on ethical practices in the 
profession.  
The sother peakers included Dr Shahzad Ahmed, 
Clinical Endocrinologist (USA), Dr Jawaid Malick, 
Rheumatologist, Fauji Foundation Hospital, 
Brigadier Tahir Aziz, Immunologist from AFIP and 
Lt Col Shakil Mirza, Hepatologist, Army Medical 
Dr Aysha Habib Khan
Chemical Pathology
Services. The presentations covered clinical 
areas like diabetes, thyroid, osteoporosis, vitamin 
D deficiency, role of autoantibodies, insulin 
resistance in liver disease, placenta and foetal well-
being, cystatin C as a marker of renal function, 
biochemical investigations in liver diseases and a 
view of novel cardiac biomarkers in heart failure.
A  wide range of topics related to laboratory science 
were also covered including metabolomic vs 
clinical chemistry, improving efficiency in clinical 
lab, the impact of STAT laboratory services in the 
management of patients, selection of a clinical 
chemistry instrument and a contrast approach 
and lines of investigation including genomics and 
metabolomics.
The post course workshop was well attended 
by postgraduate trainees. It covered instrument 
handling, scenarios related to lab management and 
data interpretations.
The Executive Council and general body meeting 
was held on March 16. The committee discussed the 
IFCC scholarship award for enhancing the skills of 
trainees under 40 years of age and increasing their 
membership. The Committee decided to hold the 
5th biennial conference of the society in February 
2013 in Karachi. 
The Executive Council thanked Brigadier Dilshad, 
organising secretary of the biennial course for his 
efforts in arranging the course. 
Participants of the course at Armed Force Institute of Pathology
hospitals.aku.edu/Karachi/pathologymicrobiology
